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Abstract
Based on recommendations of the ECIL-4, we prospectively
evaluated discontinuation of empirical antibiotic therapy in
high-risk neutropenic acute myeloid leukaemia patients with fever
of unknown origin. Seven patients (median neutropenia duration
30 days) were included. Four of them remained afebrile but
quickly recovered from neutropenia. The other three had rapid
recurrent fever. Two of these three patients had bacteraemia with
susceptible strains and one of them was transferred to the ICU for
septic shock. Median duration of sparing of antibiotics for the
seven patients was 3 days (2–4). Because of these limited results
the study was stopped.
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Although new targeted treatments in acute myeloid leukaemia
(AML) appear potentially less heamatotoxic [1], the improve-
ment in survival of these patients in the last decades has mainly
been due to the intensiﬁcation of chemotherapy and better
supportive care [2]. In most cases of febrile neutropenia,
empirical treatment with broad-spectrum antibiotics is associ-
ated with a favourable outcome. Antibiotherapy is usually
continued until marrow recovery, even in cases of fever of
unknown origin (FUO). During the induction treatment phase of
AML, this strategy implies extended periods of treatment, which
can exceed 1 month [3]. However, it has been demonstrated
that the risk of the emergence of resistant bacteria increases
with the duration of antimicrobial exposure [4]. Thus, recent
recommendations of the 4th European Conference on
Infections in Leukemia (ECIL-4) proposed the discontinuation
of antibiotics in patients with FUO who were afebrile and stable
for at least 48 h, irrespective of the neutrophil count or the
expected duration of neutropenia (available at http://www.ebmt.
org/Contents/Resources/Library/ECIL/Documents/ECIL4 2011
Bacterial resistance in Haematology.pdf).
Based on these recommendations, we prospectively evalu-
ated the discontinuation of empirical antibiotics in selected
neutropenic AML patients with FUO treated intensively in
laminar ﬂow rooms from our haematology ward. Inclusion
criteria were neutropenia (neutrophils <0.5 G/L), broad-spec-
trum antibiotic therapy for more than 7 days, apyrexia for at
least 5 days, clinical stability and no or only mild elevation of
serum markers of inﬂammation (CRP <50 mg/L, ﬁbrinogen
<6 g/L). Documented and/or clinical infection, faecal carriage
of enterobacteria resistant to broad-spectrum cephalosporins
(ER-BSC) (extended-spectrum beta-lactamase or high level
cephalosporinase-producing enterobacteria), admission to the
intensive care unit (ICU) during the ﬁrst episode of FUO,
haematopoietic stem cell transplantation, concurrent cortico-
steroid therapy, palliative care, selective decontamination and
antibiotic prophylaxis were exclusion criteria. Temperature
was monitored every 3 h after antibiotic discontinuation.
Antibiotics were reintroduced in the case of fever, deﬁned as a
single temperature measurement of >38.3°C or a temperature
of >38.0°C sustained over a 1-h period. This study was
validated by our anti-infectious agents committee at the
Gustave Roussy Institute, Villejuif, France.
Between 10 May and 21 December 2012, we treated 38
AML patients with high-risk neutropenia with 59 treatment
courses. Seven patients (7/59, 12%) with a median age of
60 years (28–66) and median neutropenia duration of 30 days
(15–44) were consecutively included in our study (Table 1).
The main reason for non-inclusion was ER-BSC faecal carriage
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(n = 20), documented infection (n = 16), clinical infection
(n = 4), hospitalization in the ICU (n = 5), corticosteroid
therapy (n = 3), duration of apyrexia less than 7 days (n = 3)
and absence of fever (n = 1). Included patients had received
antibiotics for a median duration of 15 days (8–29) for FUO
before stopping treatment. Four of them remained afebrile but
quickly recovered from neutropenia (maximum 4 days), mak-
ing sparing of antibiotics rather weak. The other three patients
had rapid (<3 days) recurrent fever. Interestingly, they expe-
rienced more than 5 days of neutropenia after antibiotic
discontinuation. Two of these three patients had bacteraemia
with susceptible strains and one of them was transferred to
the ICU for septic shock, with favourable outcome. Antibiotics
were spared for a median of only 3 days (2–4) in the seven
patients. Altogether, these modest results were weighed
against the high risk of infection incurred by the patients and
the study was quickly stopped.
ECIL-4 recommendations are based only on ﬁve studies in
adult patients [5–9]. Although these studies demonstrated the
feasibility of antibiotic discontinuation in neutropenic patients,
they have some limitations. Two studies only mentioned 10
and 16 patients, respectively [5,6]. In the three others [7–9],
patients experienced a mean duration of neutropenia of
around 7 days [7,8] after discontinuation and/or received
antimicrobial prophylaxis with ciproﬂoxacin (500 mg BID)
[8,9] which was not the case for our patients. Interestingly, the
two strains responsible of bacteraemia in our study were
susceptible to ﬂuoroquinolones. However, although it has
been shown [10] to be associated with less infectious episodes,
wide exposure to this class of antibiotics leads to an increased
incidence of resistance and limits the beneﬁts of this approach
[11]. The foundations of empirical therapy in neutropenic
patients have been validated for a long time [12] and antibiotic
discontinuation was experienced decades ago without success.
In a randomized study, Pizzo et al. [13] showed in 1979 the
higher frequency of recurrence of fever, infection and death in
high-risk neutropenic patients with FUO who discontinued
antibiotic therapy after 7 days of treatment. Although sparing
of antibiotics remains an important issue, it is difﬁcult to deﬁne
which neutropenic patients may be eligible for treatment
discontinuation.
As recommended by the ECIL4, an alternative approach to
limit the use of broad-spectrum antibiotics is the antibiotic
de-escalation from carbapenems to narrower spectrum drugs.
It is established that patients who receive high-dose chemo-
therapy have a high risk of digestive translocation [14]. We
recently showed that the level of ER-BSC faecal carriage is
correlated with this risk and could guide the choice of
antibiotic treatment (52nd Interscience Conference on Anti-
microbial Agents and Chemotherapy, Abstract D-772). Over
the same period of our study, 14 of our 38 AML patients,
during 20 treatment courses (20/59, 34%), were ER-BSC
carriers and received a carbapenem as ﬁrst-line empirical
treatment instead of cefepime or piperacillin-tazobactam.
Carbapenem treatment was usually continued until the
resolution of neutropenia, even in the absence of bactera-
emia. By analogy with our escalation attitude, guiding the
antibiotic de-escalation according to the load of ER-BSC
could be interesting to evaluate. Moreover, 60% (12/20) of
ER-BSC isolates were ﬂuoroquinolone-resistant, suggesting
that in our center there is a lack of interest in antibiotic
prophylaxis.
However, despite the possible random effect due to the low
number of patients, we believe the results of our preliminary
study may indicate that high-risk neutropenic patients are not
good candidates for discontinuation, as speciﬁed in IDSA
guidelines [15], but potentially for de-escalation. On the basis
of these limited data, the role of discontinuation of antibiotic
therapy in neutropenic patients needs to be clariﬁed by larger
prospective studies on carefully selected patients in the
current era of antibiotic sparing.
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TABLE 1. Patient characteristics
Pt
Age,
years
Treatment
phase
Neutropenia
duration,
days ATB before D
Delay ATB/
apyrexia,
days
Number of
days of ATB
Delay
D/fever,
days
Delay
D/PNN >0.5G/L,
days
Theoretical
number of
ATB D, days
Documented
infection
1 54 Induction 39 Imipenem-cilastatin 1 23 NA 4 4 NA
2 60 Induction 42 Cefepime 2 29 NA 4 4 NA
3 28 Induction 44 Imipenem-cilastatin 5 11 3 17 3 K. pneumoniae,
blood
4 61 Induction 15 Piperacillin-tazobactam 7 15 NA 2 2 NA
5 56 Consolidation 17 Piperacillin-tazobactam 3 8 2 6 2 NA
6 61 Induction 16 Piperacillin-tazobactam 1 20 NA 3 3 NA
7 66 Salvage 30 Imipenem-cilastatin 2 9 2 17 2 E. coli, blood,
septic shock
Pt, patient; ATB, antibiotic therapy; D, discontinuation; PNN, polynuclear neutrophils; G/L, Giga/litres; NA, not applicable; K. pneumoniae, Klebsiella pneumoniae; E. coli, Escherichia
coli.
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